EPISODE · Nov 12, 2013 · 40 MIN
The HD View with First HD Crew
from Help 4 HD Live! · host Help 4 HD Live!
Tuesday, November 12, 2013 Join us for an update on the HSG First-HD clinical trial with incredible special guests Jody Goldstein from Rochester and Greg Suter from the HNDC. First-HD is a Phase III clinical research trial of an investigational drug called SD-809 Extended Release (ER) in persons who have a diagnosis of Huntington disease (HD). First-HD will look at how safe, tolerable and effective SD-809 ER is compared to placebo (inactive drug) in reducing chorea. First-HD will be enrolling participants across North America (United States and Canada) who have been diagnosed with HD and who have never taken tetrabenazine (Xenazine ®, Nitoman ®). Participants will be involved in this trial for approximately 4 months. For more information about First-HD you can contact the HSG directly: Toll-free number: (800) 487-7671 (North America) OR email: [email protected] Visit: www.ClinicalTrials.gov
What this episode covers
Tuesday, November 12, 2013 Join us for an update on the HSG First-HD clinical trial with incredible special guests Jody Goldstein from Rochester and Greg Suter from the HNDC. First-HD is a Phase III clinical research trial of an investigational drug called SD-809 Extended Release (ER) in persons who have a diagnosis of Huntington disease (HD). First-HD will look at how safe, tolerable and effective SD-809 ER is compared to placebo (inactive drug) in reducing chorea. First-HD will be enrolling participants across North America (United States and Canada) who have been diagnosed with HD and who have never taken tetrabenazine (Xenazine ®, Nitoman ®). Participants will be involved in this trial for approximately 4 months. For more information about First-HD you can contact the HSG directly: Toll-free number: (800) 487-7671 (North America) OR email: [email protected] Visit: www.ClinicalTrials.gov
NOW PLAYING
The HD View with First HD Crew
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 24, 2026 ·13m
Feb 18, 2026 ·11m
Feb 17, 2026 ·9m
Feb 11, 2026 ·45m
Feb 11, 2026 ·7m